Clinical Trial Update: Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis [Phase 3]

View source ↗

Summary

Phase 3 pharmacokinetic/pharmacodynamic study evaluating high-dose rifapentine and moxifloxacin for tuberculosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Moxifloxacin (moxifloxacin)
• rifapentine (rifapentine)

Snippet

Sponsor: Centers for Disease Control and Prevention | Conditions: Tuberculosis | Phase 3 | Status: COMPLETED